Market Overview

$17 Billion HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023 -


The "HIV
Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity
and Forecast 2018-2023"
report has been added to's

The global HIV drugs market exceeded a value of US$ 17 Billion in 2017.

One of the primary factors catalyzing the growth of the global HIV drugs
market is increase in the prevalence of HIV and its diagnosis. Apart
from this, the market is also influenced by a rise in the number of
government initiatives for spreading the awareness amongst people
regarding causes, symptoms and treatments.

Moreover, the introduction of generic drugs, which are cost-effective
and chemically identical to branded drugs, act as another factor that is
contributing towards the demand for HIV drugs.

Looking forward, the market value is projected to reach approximately
US$ 21 Billion by 2023, expanding at a CAGR of more than 3% during

Market Summary:

  • Based on class, the market has been segmented into multi-class
    combination products, nucleoside reverse transcriptase inhibitors,
    non-nucleoside reverse transcriptase inhibitors, protease inhibitors,
    fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and
    HIV integrase strand transfer inhibitors.
  • On the basis of distribution channel, the market is segregated as
    hospital pharmacies, retail pharmacies, online pharmacies and others.
    Hospital pharmacies currently account for the largest share.

The competitive landscape of the market has also been examined
with some of the key players being

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global HIV Drugs Market

6 Market Breakup by Drug Class

7 Market Breakup by Distribution Channel

8 Market Breakup by Region

9 HIV Drugs Manufacturing Process

10 Competitive Landscape

Companies Mentioned

  • Boehringer Ingelheim International GmbH
  • Merck & Co.
  • Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences
  • Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure
  • Hetero Drugs
  • Mylan

For more information about this report visit

Did you know that we also offer Custom Research? Visit our Custom
page to learn more and schedule a meeting with our Custom
Research Manager.

View Comments and Join the Discussion!